Medcap Ab · OMXSTO:MCAP

Medcap Ab — Q3 2021 Earnings Presentation

16 slides from Medcap Ab's earnings presentation, 2021

  1. Slide 1: Q3 Presentation 2021

    a, ae ‘P MEDCAP INVESTOR IN LIFE SCIENCE Q3 Presentation 2021

  2. Slide 2: We create value and contribute to improved quality of life in Life Science

    We create value and contribute to improved quality of life in Life Science 2

  3. Slide 3: MedCap | An active investor in Life Science companies

    MedCap | An active investor in Life Science companies MedTech Business Area Specialty Pharma Business Area Sales by Segment (MSEK) Geographies Employees 5% 358 21% Sweden 35% Nordic 885 53% Europe 65% Listed on Stockholm 21% RoW Nasdaq Mid Cap MedTech Specialty Pharma 3

  4. Slide 4: Highlights Q3

    Highlights Q3 Q3 2021 • Sales growth • EBITDA increased by 24% excluding one- Net Sales time effects of 11.8 mSEK this quarter and (MSEK) 202.3 +15% 4.8 mSEK last year • All companies in the MedTech segment EBITDA contributed to sales and EBITDA growth (MSEK) 49.5 +41% • Strong margin (19% EBITDA-ma

  5. Slide 5: Sales and EBITDA by quarter

    Sales and EBITDA by quarter +15% Net sales per quarter (MSEK) Q3 YTD R12 250 227 223 233 211 206 209 202 Net Sales 200 200 183 173 188 186 175 +15% +12% +10% 166 160 growth 152 150 139 120 EBITDA +41% +26% +19% 100 growth 50 EBITDA- 24% 21% 21% margin 0 Q1 Q2 Q3 Q1 * Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

  6. Slide 6: Sales and EBITDA rolling 12 months by quarter

    Sales and EBITDA rolling 12 months by quarter MSEK (Net sales) MSEK (EBITDA) / % 1 000 Sales CAGR: 12% 885 900 EBITDA CAGR: 30% 858 817 834 200 786 801 800 757 763 726 739 734 186 699 709 700 672 171 639 166 157 150 596 155 600 564 147 525 540 140 141 504 508 513 500 466 127 127 439 113 100 400 300

  7. Slide 7: MedTech Q3

    MedTech Q3 Q3 2021 YTD • EBITDA growth of 45% excluding one-time Net Sales effect in Q3 2020 (MSEK) 129.8 +34% 431.2 +28% • Margin at 25%, an increase of 2 ppts if excluding one-time effect in 2020 EBITDA 32.3 +20% 115.8 +43% • Sales and earnings growth across the (MSEK) companies in the business ar

  8. Slide 8: MedTech by Company | Net Sales Rolling 12 Months Development (mSEK)

    MedTech by Company | Net Sales Rolling 12 Months Development (mSEK) Solid performance in SE and NO Continued good demand 250 160 140 200 120 150 100 80 100 60 40 50 20 0 0 19Q4 20Q1 20Q2 20Q3 20Q4 21Q1 21Q2 21Q3 19Q4 20Q1 20Q2 20Q3 20Q4 21Q1 21Q2 21Q3 Growth primarily driven by Nutrition Approaching

  9. Slide 9: MedTech | Sales and EBITDA rolling 12 months by quarter

    MedTech | Sales and EBITDA rolling 12 months by quarter Net Sales and EBITDA-margin – Rolling 12 months MSEK 700 30% ▪ R12 Net sales +26%, primarily driven by the acquisition of Multi-Ply and strong growth in Inpac and 600 577 544 25% Cardiolex 483 504 ▪ R12 EBITDA +38% 500 451 456 444 20% 424 431 4

  10. Slide 10: Specialty Pharma Q3

    Specialty Pharma Q3 Q3 2021 YTD • Sales declined in comparison to last year Net Sales • Growth in Pharma portfolio (MSEK) 72.5 -8% 227.2 -10% • Lower volumes in CDMO (still C-19 effects and some production disturbance due to new EBITDA machine installation) (MSEK) 11.2 -10% 30.8 -12% • Specialty pha

  11. Slide 11: Specialty Pharma | Sales and EBITDA rolling 12 months by quarter

    Specialty Pharma | Sales and EBITDA rolling 12 months by quarter Net Sales and EBITDA-margin – Rolling 12 months MSEK 400 16% ▪ R12 Net sales -11% 346 ▪ R12 EBITDA -10% 350 335 335 14% 327 331 331 318 316 321 320 308 309 310 309 302 300 284 12% 270 265 269 258 256 250 10% 200 8% 150 6% 100 4% 50 2%

  12. Slide 12: Sales development for portfolio of Specialty Pharma products

    Sales development for portfolio of Specialty Pharma products Portfolio of attractive products Sales development for selection of key products R12 MSEK 100.0 Attractive platform of own & partner products, pipeline with new product launches, 90.0 established expertise in product development 80.0 -1% (

  13. Slide 13: Sales and EBITDA over time

    Sales and EBITDA over time Net sales (MSEK) EBITDA (MSEK) / % 1 000 Sales CAGR: 13% EBITDA CAGR: 30% 885.4 200 900 858 817 834 800 757 186 709 171 700 166 157 150 596 600 149 525 500 466 406 423 100 400 349 337 316 300 259 78 187 59 50 200 47 45 41 43 38 100 33 27 22 0 7 0 08/09 09/10 10/11 11/12 12

  14. Slide 14: Financial Targets

    Financial Targets Net sales in 3 years Annual EBITDA growth Net debt / EBITDA 1,500 MSEK >15% <3x 14

  15. Slide 15: Investment strategy

    Investment strategy Small and mid-sized Majority Private life science companies Ownership Central / Northern Europe Unlimited Located companies with Ownership period international potential Relationship Targeting Based investments 5 – 10 core investments 15

  16. Slide 16: Thank You! Q&A

    Thank You ! Q&A Anders Dahlberg Kristina Ekblad CEO CFO [email protected] [email protected] +46 704 269 262 +46 703 322 167 16

MedCap — Q3 2021 Earnings Presentation on 6ix